-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, TcdlR5mqf6ziaB4kAsXq1BY7rMO4/lQc4u3DgyD6dqz4ZHKwOPBlq59ZiK2icYmT hsdiQ3yrKDdXevM1mHmcGQ== 0000950116-05-000926.txt : 20050307 0000950116-05-000926.hdr.sgml : 20050307 20050307170714 ACCESSION NUMBER: 0000950116-05-000926 CONFORMED SUBMISSION TYPE: AW PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20050307 DATE AS OF CHANGE: 20050307 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GENEREX BIOTECHNOLOGY CORP CENTRAL INDEX KEY: 0001059784 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 820490211 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: AW SEC ACT: SEC FILE NUMBER: 333-121456 FILM NUMBER: 05664635 BUSINESS ADDRESS: STREET 1: 33 HARBOUR SQ STREET 2: STE 202 CITY: TORONTO ONTARIO CANADA STATE: A1 ZIP: M5J 2G2 BUSINESS PHONE: 4163642551 MAIL ADDRESS: STREET 1: 33 HARBOUR SQ STREET 2: STE 202 CITY: TORONTO ONTARIO CA STATE: A1 ZIP: M5J 2G2 AW 1 aw.txt AW GENEREX BIOTECHNOLOGY CORPORATION March 7, 2005 Securities and Exchange Commission Division of Corporation Finance 450 Fifth Street, N.W. Washington, D.C. 20549 Re: Generex Biotechnology Corporation Request for Withdrawal of Amendment No. 1 to Registration Statement On Form S-3 filed on January 21, 2005 (File No. 333-121456) Accession No. 000950116-05-000234 Ladies and Gentlemen: Pursuant to Rule 477 under the Securities Act of 1933, as amended, Generex Biotechnology Corporation (the "Company") requests the withdrawal of the Amendment No. 1 to Registration Statement on Form S-3 (File No. 333-121456) that was filed with the Securities and Exchange Commission on January 21, 2005. This Amendment No. 1 to the Registration Statement was inadvertently submitted under the wrong SEC file number. The amendment should have been filed as a pre-effective amendment to Registration Statement on Form S-3, File No. 333-121309. The Company is filing a Post-Effective Amendment No. 1 to Registration Statement on Form S-3 (File No. 333-121309) on or about the time of this letter, and will request by separate acceleration request effectiveness of that post-effective amendment. If you have any questions regarding this request for withdrawal, please do not hesitate to contact Gary A. Miller of Eckert Seamans Cherin & Mellott, our outside counsel, at 215-851-8472. Sincerely, GENEREX BIOTECHNOLOGY CORPORATION By: Mark A. Fletcher ------------------------------------------------ Mark A. Fletcher Executive Vice-President and General Counsel Generex Biotechnology Corporation -----END PRIVACY-ENHANCED MESSAGE-----